Effectiveness and impact of rotavirus vaccines in Europe, 2006-2014

Vaccine. 2015 Apr 27;33(18):2097-107. doi: 10.1016/j.vaccine.2015.03.016. Epub 2015 Mar 18.


Prior to the introduction of rotavirus vaccines in 2006, rotavirus was the leading cause of severe gastroenteritis among European children <5 years of age. We conducted a systematic review of the published literature to examine the effectiveness and impact of rotavirus vaccines in Europe following the first eight years of routine use. Four publication databases were searched, yielding 276 unique citations from February 1st, 2006 to July 31st, 2014. Twenty four studies on effectiveness (n=9) and impact (n=15) met the inclusion criteria. Across Europe, vaccine effectiveness against rotavirus-related healthcare utilisation ranged from 68% to 98%, consistent with efficacy data from clinical trials. Reductions in rotavirus hospitalisations ranged from 65% to 84%, consistent with findings from post-marketing studies from the US and Latin America. We confirm the significant public health benefit of rotavirus vaccination in Europe and provide further evidence to support implementation of universal rotavirus vaccination in all European countries.

Keywords: Children; Diarrhoea; Gastroenteritis; Rotavirus; Vaccines.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Child
  • Child, Preschool
  • Europe
  • Gastroenteritis / prevention & control*
  • Hospitalization / statistics & numerical data
  • Humans
  • Latin America
  • Male
  • Product Surveillance, Postmarketing / statistics & numerical data
  • Rotavirus Infections / prevention & control*
  • Rotavirus Vaccines* / administration & dosage
  • Rotavirus Vaccines* / immunology
  • Time Factors
  • United States
  • Vaccination / legislation & jurisprudence
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / immunology


  • RIX4414 vaccine
  • RotaTeq
  • Rotavirus Vaccines
  • Vaccines, Attenuated